Notizie AIOM – anno XV
Ramalingam Expands on Osimertinib Updates in NCCN Guidelines for EGFR+ NSCLC
November 13, 2017 - The National Comprehensive Cancer Network (NCCN) unveiled its latest treatment guidelines for patients with varying histologies of non–small cell cancer (NSCLC), including those who are EGFR-mutation positive.1 One of the notable updates in this ...Leggi tutto
ASCO Endorses ASTRO Guideline on Stereotactic Body Radiotherapy for Early-Stage NSCLC
November 16, 2017 - As reported in the Journal of Clinical Oncologyby Bryan J. Schneider, MD, of the University of Michigan, Ann Arbor, and colleagues, ASCO has endorsed the recently released American Society for Radiation Oncology (ASTRO) evidence-based guideline on stereotactic ...Leggi tutto
FDA unveils a streamlined path for the authorization of tumor profiling tests alongside its latest product action
November 15, 2017 - The U.S. Food and Drug Administration today authorized Memorial Sloan Kettering Cancer Center’s (MSK) IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) tumor profiling test (assay), an in vitro diagnostic test that can identify ...Leggi tutto
FDA Approves Frontline Obinutuzumab for Follicular Lymphoma
November 16, 2017 - The FDA has approved obinutuzumab in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma, according to Genentech, the manufacturer of the therapy. The approval which ...Leggi tutto
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul tumore del pancreas è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, ...Leggi tutto
Bevacizumab Biosimilar Nears European Approval
November 10, 2017 - The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of the bevacizumab biosimilar ABP 215 for the treatment of patients across several tumor types. The positive opinion will now be reviewed by ...Leggi tutto
FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML
November 10, 2017 - The FDA has approved dasatinib for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP). The approval is based on results with dasatinib demonstrated in 97 pediatric patients ...Leggi tutto